Differential antiproliferative activity of AFP464 in human breast cancer cell lines.

aThe luminal/basal subtype obtained from Neve et al [13].
bThe TNBC subtype obtained from Lehmann et al [12].
cThe cells were treated with AFP464 for 120 h. The IC50 value was derived directly from the cell survival curve, shown as the mean value from three independent experiments.
Abbreviations: BaA, basal A; BaB, basal B; BL, basal-like; Lu, luminal; ML, mesenchymal-like; CA, carcinoma; Inf. CA, inflammatory ductal carcinoma; IDC, invasive ductal carcinoma; Norm, normal; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; P53, tumor protein 53; BRCA1, breast cancer type 1 susceptibility protein; MCF-7/Her2-18, herceptin-resistant MCF-7 cell line; MCF-7/Tam1, tamoxifen-resistant MCF-7 cell line; TNBC, triple-negative breast cancer; wt, wild type; mt, mutation; n/a, information not available.